Scheme involves expanding exisiting complex on Teesside for Japanese giant

ISG is set to start work on a vaccines manufacturing centre on Teesside worth £200m, Building can reveal.

The firm is mobilising for construction to begin in earnest by the end of the month at the plant in Billingham for a subsidiary of $21bn (£17bn) turnover Japanese multinational Fujifilm.

The work will involve expending an existing plant with 20,000 sq ft of modular clean room space, two purification suites and a column packing room.


The Diosynth Biotechnologies is part of the $21bn (£17bn) turnover Fujifilm group

The job is part of a £400m investment package at Fujifilm’s Diosynth Biotechnologies’ UK site to expand cell culture capabilities, viral vector and gene therapy services and microbial production.

At the time of the announcement in December 2021, the then prime minister Boris Johnson said: “At £400m, this is a significant investment in British biopharmaceutical manufacturing and will power our response to some of today’s most urgent global health challenges and deliver life-changing medicines and vaccines to patients in need.”

ISG, which declined to comment, is expected to finish the Fuji job by early 2025.

The contractor was working on the Britishvolt scheme 45 miles up the North Sea coast at Cambois in Northumberland until last summer.

Britishvolt collapsed into administration last week with the future of a planned £300m car battery plant now up in the air. As well as ISG, others working on the scheme included M&E specialist NG Bailey.